Colon-Targeted Drug Delivery Systems: pH-Dependent, Enzyme-Responsive, Time-Controlled, and Microbiota-Triggered Release Platforms

Abstract

Background: Colon-targeted drug delivery systems are designed to release their drug payload specifically in the large intestine while resisting premature drug release in the stomach and small intestine. The therapeutic rationale for colonic targeting encompasses two distinct but equally important goals: local therapy for diseases confined to the colonic mucosa — including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, colorectal cancer, and colonic infections — and systemic drug delivery exploiting the colon's large absorptive surface area, reduced enzymatic activity compared to the small intestine, and prolonged transit time for drugs with absorption windows in the distal gut or requiring sustained release. The colon harbors a dense and metabolically active microbiota of approximately 10 to 100 billion bacteria per milliliter of luminal content, which produces a unique enzymatic environment exploitable as a biological trigger for site-specific drug release.

Objective: This review comprehensively examines the physiological basis of colon-targeted delivery, the classification and design principles of pH-dependent, time-controlled, enzyme-responsive, pressure-activated, and microbiota-triggered colon delivery systems, preparation and characterization methodologies, therapeutic applications in IBD, colorectal cancer, and chronic systemic diseases, and the critical translation barriers that distinguish successful from unsuccessful colon-targeting approaches in clinical practice.

Results and Discussion: pH-dependent polymer coating using Eudragit S100 and Eudragit FS 30D remains the most clinically established colon-targeting strategy, exploiting the pH gradient from 1.5 to 2.0 in the stomach through 6.0 to 6.5 in the terminal ileum to 6.5 to 7.5 in the colon. Microbiota-triggered release systems utilizing polysaccharide carriers including pectin, guar gum, chondroitin sulfate, and inulin that resist enzymatic digestion in the small intestine but are fermented by colonic bacteria represent an inherently specific triggering mechanism with compelling disease-relevant applications. Nanoparticle-based colon-targeted systems demonstrate superior mucosal penetration and uptake by intestinal macrophages compared to conventional coated tablets, with particular relevance for siRNA delivery to colonic immune cells in IBD.

Conclusion: Colon-targeted drug delivery has achieved substantial clinical validation through multiple approved products for IBD management, with ongoing research in microbiota-modulating delivery, colorectal cancer targeting, and next-generation biologic delivery establishing the continued pharmaceutical relevance of this delivery approach. Critical translation barriers including inter-individual GI pH variability, microbiome compositional heterogeneity, and the poor permeability of the colonic epithelium to macromolecules remain active research priorities.